Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, Regorafenib, and HAIC in Advanced Colorectal Liver Metastases
NCT05877001Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, regorafenib in Colorectal cancer with liver metastases (CRLM), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
tislelizumabregorafenib
03
Conditions
Colorectal cancer with liver metastases (CRLM)
Beyond the preview
Go deeper on NCT05877001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05877001.